Skip to main content
Skip to navigation

Collaborative Success Stories: Take Heart

Heart and blood vessels

Dr. William Fay says a new compound can help treat coronary artery disease.

Heart disease is the leading cause of death in the United States. To treat blocked arteries, doctors use stents coated with drugs to prevent future buildup. However, these drugs can increase the risk of blood clotting and heart attack.

Fay suspected that a new compound called tiplaxtinin could prevent blockages without danger of clots. To test his theory, he gathered colleagues from the Medical School, the College of Veterinary Medicine, Dalton Cardiovascular Research Center and the chemistry department. Because pigs are considered the best animal model for human heart disease, Fay also engaged researchers from MU’s internationally-recognized Swine Resource and Research Center.

Fay’s hunch was proven correct. Tiplaxtinin is a promising new compound for use in cardiovascular treatments. In addition, MU chemists developed new methods for synthesizing tiplaxtinin and coating stents. With the research results, Fay was able to procure a $1 million grant from the National Institutes of Health.

Dr. William Fay is professor of medicine and medical pharmacology and physiology in MU’s School of Medicine.

Click here to download a PDF of this story.

Related Initiative(s):
One Health/One Medicine